KVI 020

Drug Profile

KVI 020

Alternative Names: KVI-020; WYE-160020

Latest Information Update: 17 Dec 2013

Price : $50

At a glance

  • Originator Procter & Gamble; Wyeth
  • Developer Pfizer; Procter & Gamble
  • Class Imidazolidines; Phenyl ethers; Small molecules; Sulfonamides
  • Mechanism of Action Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Supraventricular arrhythmias

Most Recent Events

  • 17 Dec 2013 No development reported - Preclinical for Supraventricular arrhythmias in USA (unspecified route)
  • 01 Oct 2013 Warner Chilcott has been acquired and merged into Actavis Inc
  • 30 Oct 2009 Warner Chilcott has acquired the global pharmaceutical business of Procter & Gamble
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top